clinical trial · NCT07238647
A Trial of HRS-5817 in Obese Participants
Atridia Pty Ltd.·early phase1·active not recruiting·n = 40
ObesityHRS-5817HRS-5817HRS-5817HRS-5817
brief summary
The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of HRS-5817 in obese participants
started
Jan 5, 2026
primary completion
Jan 30, 2027
completion
Jan 30, 2027
last updated
May 12, 2026
official title
A Phase I, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Subcutaneous Administration of Single Ascending Doses of HRS-5817 in Obese Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol